達西珠單抗

化合物

達西珠單抗INN:dacetuzumab;開發代號:SGN-40huS2C6)是一種人源化單株抗體[1]正在開發用於治療CD40陽性癌症,如非霍奇金淋巴瘤[2]血液惡性腫瘤[3]

達西珠單抗
單株抗體
種類完整抗體
目標CD40
臨床資料
其他名稱SGN-40
ATC碼
  • 未分配
識別資訊
CAS號880486-59-9  checkY
ChemSpider
  • none
UNII
化學資訊
化學式C6452H9964N1732O1998S42
摩爾質量145,111.33 g·mol−1

該藥物由西雅圖遺傳學英語Seagen公司開發。[4]

參考資料

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab頁面存檔備份,存於網際網路檔案館), American Medical Association.
  2. ^ Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. Journal of Clinical Oncology. September 2009, 27 (26): 4371–7. PMID 19636010. doi:10.1200/JCO.2008.21.3017 . 
  3. ^ Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Current Opinion in Investigational Drugs. June 2009, 10 (6): 579–87. PMID 19513947. 
  4. ^ Khubchandani, Sapna; Czuczman, Myron S.; Hernandez-Ilizaliturri, Francisco J. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Current Opinion in Investigational Drugs (London, England: 2000). 2009-06, 10 (6) [2024-03-10]. ISSN 2040-3429. PMID 19513947. (原始內容存檔於2024-03-10).